Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases

Inclusion Criteria : * Informed consent signed, * Patient affiliated to a social security system or benefiting from such a system, * Related HLA identical donor or unrelated HLA identical donor : all patients aged \> 55 years with hematological malignancy and deemed eligible for an allogeneic transplant from a geno-identical donor and pheno-identical 10/10 \- the basic pathology should be considered "chemo-sensitive" complete or partial remission (CR, PR) or stable disease Exclusion Criteria : * Pregnant or lactating woman or without contraception (for child bearing potential women) * Patient deprived of liberty or under supervision of a guardian * Impossibility to undergo medical examinations of the study for geographical, social or psychological reasons * Usual contra-indications for allogenic transplant * Aged \< 55 years * History of allogenic transplant * Concomitant neoplastic disease * Evolutive psychiatric disease * HIV seropositivity or C hepatitis under treatment * Women of childbearing age or man, in the absence of effective contraception during treatment and up to 12 months after treatment discontinuation